Programmed Cell Death News and Research

RSS

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Study uncovers new mechanism of action in a first-line drug for diabetes

For decades, metformin has been the first-line drug in the treatment of type 2 diabetes, lowering blood glucose levels by inhibiting glucose production in the liver. Metformin also improves glucose uptake and use by muscle tissue.

23 Oct 2018

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100% of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

New approach to understanding cancers will accelerate development of better treatments

A new innovation in cancer research will enable scientists to understand the complex causes of the disease with unprecedented speed and sophistication. This will accelerate the development of new and better treatments, and it will help researchers find ways around roadblocks that now stand in their path.

19 Oct 2018

Down syndrome may hold important clues to onset of Alzheimer's disease

At first glance, Down syndrome and Alzheimer's disease, two severe brain abnormalities, may seem to have little in common. Down syndrome is a hereditary disease, the source of which has long been recognized--a triplication of chromosome 21.

17 Oct 2018

Targeting a protein could be key for suppressing breast cancer metastasis, study suggests

A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a protein known as collagen XIII could be key for suppressing breast cancer metastasis.

9 Oct 2018

Non-small cell lung cancer patients survive longer when treated with durvalumab

Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.

27 Sep 2018

Study reveals structure of potential drug target in neurological conditions

Researchers at Van Andel Research Institute (VARI) have revealed the atomic-level structure of a protein that could serve as a promising new drug target for the treatment of neurological conditions such as bipolar disorder and Alzheimer’s disease.

25 Sep 2018

Researchers describe cell mechanism that optimizes proteins production in stressful situations

The different genes within the genome must be expressed in precise levels and in the exact moment if the complex balance regulating cell activity is to be maintained.

19 Sep 2018

Researchers identify key step in how plant cells respond to pathogens

Just like humans, plants have an immune system that helps them fight off infections. Plant immunity has some important differences: they don't make antibodies and can't fight off the same bug more quickly months or years later.

18 Sep 2018

Cellular environment affects type of tumor development

Liver cancer is the second leading cause of cancer death worldwide. Two different forms of primary liver cancer cover the majority of cases: About 10 to 20 percent of those affected develop a bile duct carcinoma within the liver (intrahepatic cholangiocellular carcinoma; ICC), the far higher proportion of liver cancers are hepatocellular carcinomas.

12 Sep 2018

Mitochondrial pathway found to be involved in breast cancer

Researchers have discovered a molecular pathway that controls the movement of mitochondria within breast cancer cells and influences invasiveness.

12 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Study reveals sex-specific differences in mice microglia

Researchers in Berlin have described significant differences in the brain immune cells (microglia) of male and female mice.

4 Sep 2018

Modified Nurr1 protein may pave way for new Parkinson's therapy

Researchers have modified the protein Nurr1 so that it can enter cells from the outside. Nurr1 deficiency may be one of the causes of Parkinson's disease.

31 Aug 2018

New project receives $3.2 million grant to investigate secrets of programmed cell death in Alzheimer's

Most neurons in the human brain live out their lives, enduring the processes of aging before eventually dying. Some, however, choose a more violent route: suicide.

24 Aug 2018

Study provides new clues to connection between aging and neurodegeneration

For decades researchers have worked to shed light on the causes of neurodegenerative disorders, a group of devastating conditions, including Alzheimer's and Parkinson's, that involve the progressive loss of neurons and nervous system function. In recent years, numerous factors, from genetic mutations to viral infections, have been found to contribute to the development of these diseases.

23 Aug 2018

Genetic variants impact outcome in dilated cardiomyopathy patients of African ancestry

Genetic testing is a powerful diagnostic tool that is increasingly being used for the diagnosis of dilated cardiomyopathy, a disease in which the heart becomes enlarged, making it difficult to pump blood. Cardiomyopathy affects more than 3.5 million people in the United States.

22 Aug 2018

UTA researcher receives NIH grant to explore ways to boost innate immunity

A UTA researcher has won a five-year, $1.8 million grant from the National Institutes of Health to look at new ways to harness the body's own defense responses to fight pathogens like bacteria.

21 Aug 2018